Government bans sale and manufacture of pain killer Dextropropoxyphene
As per notification vide GSR No.332 (E) Dated 23 May 2013 Government had suspended the manufacture, sale and distribution of Dextropropoxyphene and formulations containing Dextropropoxyphene for human use.
Its sale already banned in the US, UK and other countries earlier.
Product permissions granted to the manufacturers and its loan licensees to manufacture this drug and its formulations also stand suspended.
The drug must be withdrawn from the market immediately as per notification of Government of India.
Recent Posts
India as a Cosmetic Manufacturing Hub: CDSCO, BIS, and the Regulatory Enablers for Global Manufacturers
The Strategic Shift For most global Cosmetic brands, India’s regulatory journey has begun with import registration — the COS-2 pathway explored throughout this series. But for a growing ..
Post-Market Surveillance Under Medical Device Rules, 2017
Regulatory approval is often treated as the finish line. In reality, for Medical Device and IVD manufacturers in India, it marks the start of an equally demanding obligation: Post-Market Surveillance ..
How to Sequence Global and India Market Entry for Medical Devices Without Creating Regulatory Rework
One of the most avoidable and expensive mistakes in Medical Device commercialisation is Regulatory rework — the process of going back to redo documentation, testing, or submissions because the..
Need Help?
Submit your EnquiryOffice Locations
- Delhi
- Bangalore
- USA
- Singapore